2017 Fast Lane Honoree NuvOx Pharma
The Human Brain is our most complex organ. Everything we are and everything we do is controlled by our brain. NuvOx Pharma is a biotechnology company based in Tucson, Arizona that is developing an innovative nanotechnology for oxygen delivery to treat life-threatening diseases where hypoxia plays a role like cancer, stroke, sickle cell disease, hemorrhagic shock, traumatic brain injury, and heart attack. Hypoxia is when there is a deficiency in the amount of oxygen reaching the tissues. NuvOx is currently in clinical trials for brain cancer and stroke.
Leadership Conversation with Nobel Laureate Leland Hartwell, PhD
How will we create sustainable health? What innovations can make a difference? What is the role of education? Lee Hartwell, PhD, is the Virginia G. Piper Chair in Personalized Medicine at the Center for Sustainable Health, Biodesign Institute, Arizona State University. At the Center his work focuses on creating effective learning environments. The first is a course required for all K-8 teachers, Sustainability Science for Teachers and the second is Project Honey Bee, an interdisciplinary research project to validate wearable devices for ambulatory patient management. He also oversees a project to develop biomarkers for the clinical management of many diseases at the Chang Gung Memorial Hospital and University in Taipei, Taiwan. Dr. Hartwell was awarded the 2001 Nobel Prize in Physiology or Medicine for identifying genes that control cell division in yeast.
The Precision Medicine Initiative®
Dr. Akinlolu (“Lolu”) Ojo, Associate Vice President for Clinical
Research and Global Health Initiatives, University of Arizona Health Sciences
Akinlolu O. Ojo, MD, MPH, PhD, MBA, is the associate vice president for clinical research and global health initiatives at the University of Arizona Health Sciences and a professor of medicine in the UA College of Medicine – Tucson with a joint appointment as professor of health promotion sciences in the UA Mel and Enid Zuckerman College of Public Health.
2017 Fast Lane Honoree Avery Therapeutics
More than 26 million people worldwide suffer from heart failure and the number of cases is increasing at more than 13% per year. In the US, heart failure is the number one cause of hospital readmissions in patients over 65 and results in over $39 billion in treatment costs annually. The progression of heart failure results in a 50% mortality rate within 5 years of diagnosis. But what if it didn’t have to be like this? That is a question being addressed by the team at Avery Therapeutics, Inc. The startup company is based on the application of technology invented at the University of Arizona College of Medicine-Tucson and the Southern Arizona VA. In 2017, Avery Therapeutics licensed the beating heart graft technology from the University of Arizona. Pre-clinical studies have already shown that the technology, called MyCardia™, improves heart function.